A Phase 3 interventional study of Recombinant Tissue Plasminogen Activator (rt-PA) and Intra-arterial Thrombolysis in Medium Vessel Occlusion and Ischemic Stroke, Acute, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Tissue Plasminogen Activator in Ischemic Stroke — 4 open to participants now, 4 under way, 3 of them phase 3. Tissue Plasminogen Activator · Ischemic Stroke.
Among the 25 studies testing Tissue Plasminogen Activator in Ischemic Stroke, this one is the 9th largest by planned enrollment, is one of 2 that started in 2026, is one of 12 in phase 3, and was the 24th registered.
2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.
Browse Ischemic Stroke studies →4 of the 25 studies testing Tissue Plasminogen Activator in Ischemic Stroke are open now, in 6 countries. Recruiting first, the newest first:
115 People's Hospital · Sites in Vietnam
Ages 18+
Guri Hagberg · Sites in Denmark, Norway, Sweden
Ages 18+
Kafrelsheikh University · Sites in Egypt
Ages 18–75
By country, each count listing its studies:
Tissue Plasminogen Activator: first FDA approval 1987 (ACTIVASE). What it is approved for, and how studies give it, is on its page →
Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 372 is above the median of 120 across 1,785 interventional studies indexed under Ischemic Stroke.
Median enrollment 234 across the 25 interventional studies. Of the 19 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 568 studies on the registry; 317 are open to participants now.
The First Affiliated Hospital with Nanjing Medical University has 5 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing Tissue Plasminogen Activator in Ischemic Stroke, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) phase III trial is planned to evaluate the efficacy and safety of intra-arterial thrombolysis (IAT) in patients with acute ischemic stroke caused by medium vessel occlusion (MeVO, distal M2 [above the mid-insular height], M3 or M4; A2, A3 or A4; or P2 or P3 segments, confirmed by CTA or MRA), compared with best medical management alone. Eligible participants (aged 18-80 years, baseline NIHSS score 6-25, confirmed MeVO within 24 hours of symptom onset or last known well) will be randomly assigned 1:1 to the intra-arterial thrombolysis plus best medical management group or the best medical management alone group.
The primary endpoints are (i) the proportion of patients with a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-2 at 90±7 days post-randomization; (ii) the proportion of patients with symptomatic intracranial hemorrhage (sICH) within 48 hours post-randomization, defined and classified according to the Heidelberg Bleeding Classification; and (iii) the proportion of patients with early neurological deterioration (END) within 7 days post-randomization, defined as an increase of ≥ 4 points in the total NIHSS score from baseline or an increase of ≥ 2 points in any single NIHSS item.
Secondary endpoints:
With the continuous advancement of endovascular techniques and the widespread adoption of mechanical thrombectomy, endovascular treatment has become the standard of care for acute ischemic stroke caused by large vessel occlusion. However, the optimal management strategy for acute ischemic stroke caused by medium vessel occlusion (MeVO) remains an unmet clinical need. MeVO accounts for approximately 25-40% of all acute ischemic strokes and is associated with substantial morbidity, yet existing evidence from recent randomized controlled trials, including DISTAL and ESCAPE-MeVO, has failed to demonstrate a clear benefit of mechanical thrombectomy over best medical management alone in this population. Potential reasons include the limited suitability of current thrombectomy devices-which were primarily designed for large vessel occlusions-for more distal and tortuous medium vessels, leading to lower recanalization rates and increased risks of vessel perforation, dissection, and vasospasm. Moreover, the significant heterogeneity in patient selection across previous trials, particularly the lack of unified imaging inclusion criteria, may have diluted the potential treatment effect in specific subgroups.
Intra-arterial thrombolysis (IAT), as an alternative endovascular approach, offers theoretical advantages for MeVO. By delivering thrombolytic agents directly into or adjacent to the thrombus via a microcatheter, IAT achieves high local drug concentrations while minimizing systemic exposure. Evidence from the PROACT II study demonstrated that intra-arterial prourokinase significantly improved 90-day functional outcomes in patients with middle cerebral artery occlusion compared with heparin alone. More recently, the CHOICE trial showed that adjunctive intra-arterial alteplase following successful thrombectomy improved functional outcomes in large vessel occlusion stroke. These findings suggest that IAT may effectively dissolve residual thrombi in distal vascular beds and improve microcirculatory reperfusion-mechanisms particularly relevant to MeVO, where thrombus burden is generally smaller and the target vessels are more amenable to pharmacological dissolution.
Despite these promising signals, no dedicated randomized controlled trial has specifically evaluated IAT as a primary treatment strategy for MeVO. Current guidelines provide no clear recommendation for or against endovascular treatment in this population, reflecting the urgent need for high-quality evidence. Furthermore, the optimal patient selection criteria-including imaging parameters (perfusion mismatch), clinical severity thresholds (NIHSS range), and the distinction of isolated medium vessel occlusion from other stroke subtypes-remain to be defined to maximize the therapeutic benefit.
This study intends to conduct a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) phase III trial to compare the clinical outcomes of intra-arterial thrombolysis plus best medical management versus best medical management alone in patients with acute ischemic stroke due to medium vessel occlusion. A total of 372 eligible patients (aged 18-80 years) with confirmed isolated MeVO (distal M2 [above the mid-insular height], M3 or M4; A2, A3 or A4; or P2 or P3 segments, confirmed by CTA or MRA), a baseline NIHSS score of ≥ 6 and ≤ 25, and randomization within 24 hours of symptom onset or last known well will be enrolled. The trial is powered to detect an absolute difference of 15 percentage points in the primary endpoint (67.0% vs 52.0%), with 80% power at a two-sided alpha of 0.05; assuming a 10% dropout rate, 372 patients (186 per group) will be enrolled, of whom approximately 334 are expected to complete follow-up. For patients presenting beyond 6 hours, perfusion imaging criteria (Tmax > 6 s volume ≥ 10 mL and core infarct volume [rCBF \< 30%] \< 50% of the Tmax > 6 s volume) will be applied to select those with salvageable brain tissue. Participants will be randomly assigned 1:1 by central web-based randomization, stratified by occlusion site, to receive either intra-arterial thrombolysis (alteplase 0.225 mg/kg, maximum 22.5 mg, or tenecteplase 0.0625 mg/kg, maximum 6.25 mg, consistent with the intravenous thrombolytic agent administered, delivered via microcatheter as contact thrombolysis or as a distal-to-proximal segmented infusion over 15-30 minutes) plus best medical management, or best medical management alone.
The study is led by the First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital, the sponsor and coordinating center), with 27 participating centers across China to be activated in a staged manner (the first phase comprises 10 experienced centers, including the coordinating center). An independent Data Safety Monitoring Board (DSMB) will oversee the trial, meeting every 6 months with one planned interim analysis using an O'Brien-Fleming-like alpha-spending function (two-sided alpha of approximately 0.003 at the interim analysis, to be performed when approximately 147 patients-44% of the planned final analysis population of 334-have completed 90-day follow-up, anticipated in September-October 2027). The total study duration is 3 years (June 2026 to May 2029), with enrollment anticipated to be completed within 24 months (September 2026 to August 2028). The results of this trial are expected to provide high-level evidence on whether intra-arterial thrombolysis offers a safe and effective treatment option for patients with acute ischemic stroke due to medium vessel occlusion, potentially establishing a new standard of care in this underserved population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive intra-arterial thrombolysis (IAT) via microcatheter plus best medical management (BMM). For small thrombus, microcatheter is positioned adjacent to or within the thrombus. For larger burden, microcatheter is advanced through the occluded segment with staged administration from distal to proximal portions (one-third of total dose per segment). Agent: alteplase 0.225 mg/kg (max 22.5 mg) or tenecteplase 0.0625 mg/kg (max 6.25 mg), administered over 15-30 min, consistent with any prior IV thrombolysis. Procedure ends at meTICI ≥ 2b or when risks outweigh benefits. BMM includes antiplatelet, anticoagulation (if indicated), statins, BP/glycemic control, and rehabilitation.
Drug: Recombinant Tissue Plasminogen Activator (rt-PA) · Procedure: Intra-arterial Thrombolysis · Drug: Best Medical Management · Procedure: Rescue therapy
Participants receive best medical management alone per local guidelines, including antiplatelet therapy, anticoagulation (if indicated), statins, blood pressure and glycemic control, and rehabilitation. No endovascular intervention is performed as part of the randomized treatment; protocol-specified rescue therapy is the only exception.
Drug: Best Medical Management · Procedure: Rescue therapy
Administered intra-arterially via microcatheter. Agent options: alteplase (rt-PA) at 0.225 mg/kg (maximum 22.5 mg) or tenecteplase (TNK) at 0.0625 mg/kg (maximum 6.25 mg), infused over 15-30 minutes. The choice of agent should be consistent with any prior intravenous thrombolysis.
Also known as: Tenecteplase (TNK)
Microcatheter is navigated to the occluded medium vessel. For small thrombus burden, positioned adjacent to or within the thrombus. For larger burden, advanced through occluded segment with staged administration distal-to-proximal (one-third per segment). Procedure ends at meTICI ≥ 2b or when risks outweigh benefits.
Best medical management per local guidelines, including antiplatelet therapy, anticoagulation (if indicated), statins, blood pressure and glycemic control, and rehabilitation.
Rescue intra-arterial thrombolysis is permitted in both treatment groups, including participants randomized to best medical management alone, if neurological deterioration occurs after randomization, defined as an increase of ≥ 4 points in the NIHSS score from baseline after exclusion of non-stroke causes such as hypoglycemia, infection, or metabolic derangement, with imaging evidence of salvageable brain tissue (Tmax \> 6 s volume ≥ 10 mL and core infarct volume \[rCBF \< 30%\] \< 50% of the Tmax \> 6 s volume), and provided that rescue therapy can be initiated within 24 hours of symptom onset or last known well. Rescue endovascular therapy is limited to intra-arterial thrombolysis and administered with same agents (alteplase or tenecteplase) at the same doses specified for the intra-arterial thrombolysis intervention; thrombectomy devices, balloon angioplasty, and stenting are not permitted.
Proportion of patients with favorable functional outcome at 90 days
Favorable functional outcome is defined as a modified Rankin Scale (mRS) score of 0 to 2, assessed at 90±7 days post-randomization. The mRS is a 7-point ordinal scale (range 0-6) measuring functional independence and disability, with 0 indicating no symptoms and 6 indicating death.
Time frame: 90 days post-randomization (90±7 days)
Proportion of patients with symptomatic intracranial hemorrhage at 48 hours
Symptomatic intracranial hemorrhage (sICH) within 48 hours post-randomization, defined according to the Heidelberg Bleeding Classification.
Time frame: 48 hours post-randomization
Proportion of patients with early neurological deterioration at 7 days
Proportion of patients with early neurological deterioration (END) within 7 days post-randomization, defined as an increase of ≥ 4 points in total NIHSS score from baseline, or an increase of ≥ 2 points in any single NIHSS item.
Time frame: 7 days post-randomization
Proportion of patients with procedure-related complications
Proportion of patients experiencing procedure-related complications associated with intra-arterial intervention, including but not limited to vessel perforation, dissection, distal embolization, and vasospasm.
Time frame: Within 24 hours post-randomization
Recanalization rate at 24 hours
Proportion of patients achieving successful recanalization, defined as meTICI (modified expanded Thrombolysis in Cerebral Infarction) grade ≥ 2b, assessed at 24±12 hours post-randomization by CTA or MRA.
Time frame: 24±12 hours post-randomization
Proportion of patients with any intracranial hemorrhage at 48 hours
Proportion of patients with any type of intracranial hemorrhage occurring within 48 hours post-randomization, including site and type classified according to the Heidelberg Bleeding Classification.
Time frame: 48 hours post-randomization
Early neurological improvement at 7 days
Change in National Institutes of Health Stroke Scale (NIHSS) score from baseline to 7 days post-randomization or at hospital discharge, whichever occurs first.
Time frame: 7 days post-randomization or hospital discharge, whichever occurs first
Overall distribution of functional outcomes at 90 days
Shift analysis of the full distribution of modified Rankin Scale (mRS) scores (0-6) at 90±7 days post-randomization, assessing the shift toward better functional outcomes.
Time frame: 90±7 days post-randomization
Proportion of patients with excellent functional outcome at 90 days
Proportion of patients achieving excellent functional outcome, defined as modified Rankin Scale (mRS) score of 0 to 1, at 90±7 days post-randomization.
Time frame: 90±7 days post-randomization
Proportion of patients with functional independence at 90 days
Proportion of patients achieving functional independence, defined as Barthel Index score of 95 or 100, at 90±7 days post-randomization. The Barthel Index is a 10-item scale (range 0-100) measuring activities of daily living, with higher scores indicating greater independence.
Time frame: 90±7 days post-randomization
Health-related quality of life at 90 days
Health-related quality of life assessed by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire at 90±7 days post-randomization. The EQ-5D-5L measures mobility, self-care, usual activities, pain/discomfort, and anxiety/depression on a 5-point severity scale.
Time frame: 90±7 days post-randomization
All-cause mortality at 90 days
Proportion of patients who die from any cause within 90±7 days post-randomization.
Time frame: 90±7 days post-randomization
Rescue therapy rate
Proportion of participants who receive rescue intra-arterial thrombolysis after randomization for neurological deterioration defined as an increase of ≥ 4 points in the NIHSS score from baseline (after exclusion of non-stroke causes such as hypoglycemia, infection, or metabolic derangement), with imaging evidence of salvageable brain tissue (Tmax \> 6 s volume ≥ 10 mL and core infarct volume \[rCBF \< 30%\] \< 50% of the Tmax \> 6 s volume), and provided that rescue therapy is initiated within 24 hours of symptom onset or last known well. Rescue endovascular therapy is limited to intra-arterial thrombolysis; thrombectomy devices, balloon angioplasty, and stenting are not permitted.
Time frame: Within 24 hours post-randomization
Plan to share: Undecided — The steering committee has not yet finalized the specific IPD sharing plan, including the data repository platform, timeframe, and access review procedures. This will be determined prior to the primary publication and updated on ClinicalTrials.gov at that time.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jan 2029, 28 months after the start.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 28 months is below that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tissue Plasminogen Activator
The First Affiliated Hospital with Nanjing Medical University →